Laura Coruzzi

Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI.

Meso Scale Diagnostics LLC develops and markets solutions for multiplex biological assays. Its products include angiogenesis and vascular, bone metabolism, cytokine and chemokine, inflammation, intracellular signaling, neurodegeneration, toxicology, and immuno assay kits. The firms services include assay development, custom conjugation, prototype printing, instrument services and warranties. The company was founded in 1995 and is headquartered in Rockville, MD.

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

FOXKISER LLP engages in the provision of strategic advice and counseling services to pharmaceutical and biotechnology companies. Its project works fall into three general categories: advisory services; long-term partnerships; and new company formation. The company was founded by John Daniel Kiser and Allan M. Fox in September 1986 and is headquartered in Washington, DC.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.

Wellstat Management Co. LLC provides management, legal, financial, human resources, information technology, business development, transactional, investment, licensing, and other services to the Wellstat group of companies. The company was founded by Samuel J. Wohlstadter in 2007 and is headquartered in Rockville, MD.

Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The company is based in New York, NY.

Part of CRA Holdings LLC, Chicago Center for Clinical Research is an American company that provides clinical research services. The company was founded by Michael H. Davidson.

The National Lipid Association aims to improve the practice of lipid management in clinical medicine. The non-profit company is based in Jacksonville, FL and has subsidiaries in the United States. The organization's mission is to enhance lipid management in clinical medicine, and its goals are consistent with this mission statement.

Inositec AG develops small molecules as alternatives to antibiotics. It also develops a non-antibiotic small molecule that neutralizes the toxins secreted by clostridium toxins. The company was founded by Mattias Ivarsson, Bastien Castagner and Jean-Christophe Leroux in December 2015 and is headquartered in Zurich, Switzerland.

The American College of Chest Physicians is a leading organization in clinical chest medicine, with over 19,000 members providing patient care in pulmonary, critical care, and sleep medicine in more than 100 countries worldwide. The non-profit company is based in Northbrook, IL. The organization offers access to clinical guidelines, new research, and clinical topic collections through their website, as well as opportunities for members to become more involved in the chest medicine community. The organization's mission is to promote the prevention, diagnosis, and treatment of chest diseases through education, communication, and research. Robert A. Musacchio has been the CEO of the company since 2015.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

American College of Cardiology Foundation provides cardiovascular education services. Its services include cardiac surgery, chronic angine, diabetes, geriatric cardiology and heart failure and cardiomyopathies. The company was founded by Franz Groedel, Robert P. Glover and Bruno Kisc in 1949 and is headquartered in Washington, DC.

Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million.

NanoPhoria Srl is an Italian company that operates as a non-viral drug delivery platform. The company is based in Milan, Italy. The company was founded by Daniele Catalucci, Michele Iafisco, Alessio Alogna, Claudio de Luca. Claudio de Luca has been the CEO since incorporation.

Taconic Biosciences, Inc. provides research rodents and related products and services. It offers monoclonal antibody production, drug safety testing and other services. The firm also provides contract breeding solutions, animal models, Taconic transgenic exchange, custom model generation, contract research solutions, and research services. The company was founded by Robert K. Phelan in 1949 and is headquartered in Rensselaer, NY.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Trofi Nutritionals, Inc. is a private company located in the US that is focused on advancing personal health management through next-generation nutritional wellness solutions. The American company works with partners to translate functional compound discoveries into nutritional solutions.

SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation.

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.

Jocasta Neuroscience, Inc. provides biological products development services. The company is based in New Castle, DE.

Abcentra, Inc. is an American clinical-stage biopharmaceutical company that specializes in developing novel antibody therapies for inflammatory diseases, with a particular focus on cardiovascular disease. The private company's patented technology allows for the targeting of oxidized lipoproteins and associated inflammatory responses. Abcentra's pipeline focuses on patient populations with high-risk of cardiometabolic complications that are exacerbated by chronic inflammation, including patients with inflammatory diseases and patients with residual inflammation. The company's lead compound, orticumab, is a novel monoclonal antibody that blocks inflammation from oxidized low-density lipoprotein and is slated to begin a phase 2 study later this year. Kevin B. Bacon has been the CEO of the company since 2020.